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ABSTRACT 
This thesis presents a complete, comprehensive and stepwise approach of translational 
molecular research. Starting from whole-genome bioinformatics analyses based on the 
embryonic stem (ES) cell hypothesis, a three-gene signature was identified, validated with the 
goal of clinical application in order to optimize treatment decision based on improvement of 
overall survival estimation.           
In Paper I, we hypothesized that gene signatures of embryonic stem (ES) cells may have 
prominent importance to determine the tumor subtypes and may be associated with the 
prognosis of various cancers including prostate cancer (PCa). Using published microarray 
datasets, 641 embryonic stem cell gene predictors (ESCGPs) were identified.  Using gene 
expression patterns of these 641 ESCGPs tumor subtypes of different cancers can be 
stratified, particularly for prostate cancer. We further analyzed the gene expression levels of 
selected ESCGP genes in fresh-frozen fine needle aspiration biopsy samples taken from a 
Swedish cohort of 189 prostate cancer patients. The registry follow-up period for these 
patients was up to18 years, where 97.9% patients had overall and cancer-specific survival 
data. As a result, a three-gene signature (VGLL3, IGFBP3 and F3) was identified sufficient 
to categorize the patients into high-risk, intermediate-risk and low-risk subtypes directly 
correlated with the overall and cancer-specific survival. 
Currently, formalin-fixed paraffin embedded (FFPE) prostate core needle biopsy material is 
the most common sample material available in clinical practice, on which Gleason grading 
for prostate cancer diagnosis is usually conducted. Since each patient typically has multiple 
biopsy samples, and since Gleason grading is an operator dependent procedure known to be 
difficult, the impact of the operator’s choice of biopsy was evaluated in paper II. We analyzed 
expression levels of the three-gene signature identified in paper I, using a four multiplex one-
step RT-qPCR kit specially designed and optimized for measuring the three-gene expression 
signature in 127 FFPE prostate core needle biopsy samples taken from 43 patients.  Our 
results show that the assessment of expression levels of two highly expressed genes (IGFBP3 
and F3) in prostate cancer tissue is independent of Gleason patterns. These findings indicate 
that the impact of operator’s choice of biopsy is low. 
In paper III, we carried out a new cohort study including 241 prostate cancer patients with 6-9 
years of registry follow up in order to verify the prognostic value of the three-gene expression 
signature in FFPE prostate core needle biopsy tissue samples. The cohort consisted of four 
patient groups with different survival times and cause of death (COD). We observed that 
supplementing readily available clinical data with gene expression levels of IGFBP3 and F3 
in FFPE PCa biopsy tissues could improve survival prediction for PCa patients at time of 
diagnosis. 
Based on the above work, a so-called Prostatype test system has been industrially designed 
and developed for clinical application. It integrates a robust multiplex RT-qPCR kit to 
measure expression levels of the three-gene signature and, a database of reference patients 
with accurate clinical documentation using a kNN-algorithm called CPMA (Classification of 
Prostatic Malignancy Algorithm). The survival prediction in relation to different treatment 
modalities can greatly assist both clinicians and patients to make an individualized treatment 
decision. 
The flowchart in Figure 1 summarizes the present thesis.         
  
Figure 1. Graphic summary of the present thesis. A. A step-wise gene selection process, 
starting from bioinformatics analyses of the whole genome expression data of 24361 genes 
derived from 5 human embryonic stem cell lines, identified 641 Embryonic stem cell gene 
predictors (ESCGPs), until the identification of a three-gene signature. (Right vertical 
description: methodologies used in each step; left vertical description: materials used in each 
step of study). B. Cohorts represented in the order in which they were used for the pilot study 
(Paper I), the validation study (Paper II, III) and studies for filling CPMA reference database. 
The blue cycles are ready completed and ongoing cohort studies; the green cycle shows 
cohort studies planned in the near future. C. An industrially developed Prostatype Test 
System works according to the presented workflow. The system is composed of two parts: 
Prostatype RT-qPCR kit and CPMA software. It can provide prognostic statements assisting 
individualized/personalized estimation of overall survival time and decision of treatment for 
newly diagnosed prostate cancer patients.  
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INTRODUCTION 
1 PROSTATE CANCER- A MAJOR CLINICAL 
CHALLENGE 
The prostate gland fulfills important functions in male reproductive system. Despite its small 
size in proportion to the whole body, malignant disease affecting this organ, prostate cancer 
(PCa), is the most common type of cancer in adult men. Since the introduction of the 
Prostate-specific antigen (PSA) test and ultrasound-guided multicore prostate biopsy, PCa is 
now easily detected and diagnosed at early stage. However, it is a major clinical challenge to 
decide whether a patient should be radically treated or not. Because some PCa tumors 
progress rapidly to life-threatening conditions, while the majority of early detected PCa are 
less aggressive and not life-threatening. However radical treatments often lead to life-long 
complications or severe side effects.    
1.1 DISCREPANCY BETWEEN INCIDENCE AND MORTALITY OF PROSTATE 
CANCER 
Over the past two decades, the incidence of PCa in developed countries has dramatically 
increased, while mortality rates remain largely unaltered (Figure 2) (1). In Sweden, for 
example, the number of newly diagnosed PCa patients increased from 4 000 up to 10 000 
from 1970 to 2010, while maintaining approximately 2 400 deaths annually (Figure 3).  
  
Figure 2. Reported age-standardized prostate cancer incidence and mortality rates per 
100 000 men in USA, Canada, England and Australia. Feletto E, Bang A, Cole-Clark D, 
Chalasani V, Rasiah K, Smith DP. An examination of prostate cancer trends in Australia, 
England, Canada and USA: Is the Australian death rate too high? World journal of urology. 
2015 Feb 20. PubMed PMID: 25698456. 
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This is mainly due to the factor that prostate-specific antigen (PSA) was introduced as a first 
blood biomarker in the 1990s and has been used in the PCa screening since then. A review 
study reported a dramatically increased number of diagnosed PCa cases in most of developed 
countries, particularly in USA, Canada and Australia, with so-called ‘PSA-screening peaks’ 
(Figure 2) (1). In Europe, England and Sweden, similar increasing patterns were observed 
although high detection peaks were occurred slightly later (Figure 2 and Figure 3). PSA 
screening tests have led to a higher detection rate of early-stage PCa patients including those 
with aggressively growing tumors. These patients with rapidly growing tumors benefit from 
early detection and treatment initiation. However, the PSA test also detects a large number of 
patients with indolent tumors due to its limited specificity to distinguish aggressive tumors at 
early stage from indolent ones (2, 3). 
 
Figure 3. Age-standardized PCa incidence and mortality rates per 100 000 men in 
Sweden. Swedish data recourse: the National Board of Health and Welfare, 
www.socialstyrelsen.se 
Based on these observations, two big nationwide studies investigating the benefit from PSA 
screening test were carried out in the first decade of the 21st century. However, the recently 
reported results of these two studies with long-term follow-up suggested, that the survival 
benefit due to the PSA screening for PCa diagnosis is controversial (4, 5). Even though 
European and Swedish data show that the PSA screening has substantial and significant 
benefits regarding  PCa-specific mortality after 13 years of follow-up, there was a clear 
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evidence that over-diagnosis and overtreatment are major adverse effects of PSA screening 
(6).  
1.2 HETEROGENEITY OF PROSTATE CANCER 
PCa is known for its heterogeneity in epidemiological, genetic, pathological, biological and 
clinical observations. The above big discrepancy between incidence and mortality rates of 
PCa is a typical example.  
Clinically, a group of PCa tumors could rapidly progress to metastatic disease and becoming 
lethal, while fairly large numbers of PCa tumors often grow slowly and indolently. As a 
major treatment for clinically advanced and metastatic PCa, hormone treatment or androgen 
deprivation therapy (ADT) can almost achieve complete biochemical and clinical responses 
for most patients but castration resistance would be eventually developed. Metastatic 
castration resistant prostate cancer (mCRPC) is the major cause of cancer-specific death. 
However, the time of progressing mCRPC varies dramatically in different patients with a 
range of from a few months up to several years. Similarly there is the pathological 
heterogeneity, represented by different GS in different patients (or prostates) and different 
Gleason grading patterns in coexisting multiple foci in the same prostate.  
It has been speculated that the above clinical and pathological heterogeneity is determined by 
the profound genetic or genomic heterogeneity. Previous researches, including the whole 
genome analyses by gene expression microarrays (7) and next generation sequencing, have 
identified different constitutional genetic loci, chromosomal rearrangements (8-10), gene 
expression and mutation patterns being associated with different clinical and pathological 
outcomes (11-13). Therefore, molecular biomarkers might have the potential to 
fundamentally distinguish various tumor subtypes with different biological aggressiveness 
that consequentially determining different clinical outcomes, thus further improving the 
prognosis estimation accuracy and treatment decision.   
Clearly this heterogeneity between tumors in different patients presents the urgent need for 
the identification and application of prognostic and predictive biomarkers. However, the 
heterogeneity of cancer cells within the same patient might cause difficulties for the selection 
of representative samples for the process to develop a clinically applicable biomarker test. 
That is to say, a clinically applicable and reliable biomarker test should be able to confront 
and solve the inconvenience caused by the cancer cell heterogeneity derived from the same 
patient (prostate), also able to distinguish between different tumor subtypes existing in 
different patients (prostates). 
2 PROSATE CANCER DIAGNOSIS  
Prostate cancer develops from the prostate glandular epithelium. The glandular cells produce 
PSA, a protein with protease function, which constitutes an important component in the 
semen. Normally, PSA does not enter the blood stream. Under disease conditions however, 
and particularly in prostate cancer, PSA can enter the blood circulation and is thereby 
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detectable in blood samples. This is primarily due to the disruption of local blood-tissue 
barriers by cancer cell invasion or metastasis.  In the clinical routine, an abnormally increased 
PSA value or a suspicious digital rectal exam (DRE) result is usually indicative for prostate 
core needle biopsies to confirm the existence of malignant cells and thus the diagnosis of PCa 
(14) . With seldom exceptions of patients with significantly high PSA and metastatic disease, 
the diagnosis of PCa, in particular for patients with localized disease, the diagnosis of PCa 
can only be made or confirmed by histopathological diagnosis presented as a pathological 
anatomical diagnosis (PAD) report.  
2.1 GLEASON SCORE (GS) 
Based on the histopathological morphology of cancer tissue in biopsies, a Gleason grading 
can be conducted as the Gleason score (GS) reflecting the aggressiveness of a tumor. The GS 
is composed of two values: (1) the primary Gleason pattern representing the most 
predominant pattern observed in core needle biopsies, and (2) the secondary Gleason pattern 
referring to the secondary most common pattern (15).  
The Gleason grading system was firstly invented by Dr. Donald F. Gleason in 1966 to assign 
prostatic carcinoma different grades of severity, based on the histopathological morphology 
pattern of tumor under fairly low magnification microscopic examination (16). Thus, Gleason 
grading is focused on the morphological structures of the cancer tissue instead of grading the 
dedifferentiation of individual cancer cells. The Gleason grading system classifies tumors 
into five grades ranging from grade 1 to 5 with increasing tumor aggressiveness as compared 
to normal prostatic glandular architectures. In order to solve the inconvenience caused by the 
histopathological heterogeneity within the same prostate, Gleason score (GS) is composed of 
two grades. The predominant pattern is identified as the primary Gleason grade and the 
second common pattern as the secondary Gleason grade, and the GS is generated as the sum 
of the primary grade plus the secondary grade. For example, a tumor with a primary Gleason 
pattern of grade 3 and the secondary Gleason pattern of grade 4 would equal, GS=3+4=7.  
Since the 1970s the Gleason grading system has been the gold standard when diagnosing 
prostatic carcinoma, however changes of many factors over the years have affected the 
grading results. For instance, due to early detection, many patients are asymptomatic at time 
of diagnosis. Consequently, high GS is much less common in current patients, instead a large 
number of patients have a GS of 6 or 7 with less distinguishing precision. Since the 1980s, 
thinner 18-gauge needles have been used to take sextant multiple biopsies in contrast to the 
original thicker and less number of core biopsies on which the Gleason grading system was 
developed. With the introduction of immunohistochemical staining of prostatic basal cell 
markers, Gleason grade 1 is now only classified as atypical adenomatous hyperplasia instead 
of carcinoma, and the cribriform high grade prostatic intraepithelial neoplasia (HGPIN) 
should be classified as the cribriform like ductal adenocarcinoma. Thus, the international 
society of urological pathology (ISUP) had the consensus meetings in 2005 in order to 
modify and update Gleason grading system trying to adapt to the current clinical situation. 
Consequently some modifications and adjustments have been made (Figure 4) (15).   
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Despite the above efforts, there is still a significant number of cases showing mis-grading or 
up/under-grading of GS due to the fact that the Gleason grading system is highly operator-
dependent (17). For genomic biomarker tests which highly rely on the Gleason patterns, it is 
practically problematic to select the representative sample from multiple core biopsies. 
Consequently, it needs to be evaluated whether the significance of biomarkers is dependent 
on the GS derived from different patients (prostates), and if the significance is dependent on 
the Gleason pattern of cancerous cells taken from the same patient (prostate). In paper II and 
III, we addressed those questions. Ultimately, an operator independent pathological grading 
system, e.g. a digital imaging-based algorithm that could automatically generate a better and 
more objective GS, would be a promising diagnostic tool that could aid pathologists in 
improving diagnostic results in the future. 
 
Figure 4. Schematic diagram of modified Gleason grading system. Epstein JI, Allsbrook 
WC, Jr., Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological 
Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. The 
American journal of surgical pathology. 2005 Sep;29(9):1228-42. PubMed PMID: 16096414. 
2.2 PROSTATE CANCER STAGING 
Apart from PCa diagnosis, disease staging also plays an important role in determining 
treatment decision-making.  There are different staging modalities to define and present the 
extent of local invasion and distant metastasis, such as clinical staging by DRE, imaging 
staging by ultrasound, magnetic resonance imaging (MRI) and bone scan to distinguish 
between localized, locally advanced and metastatic disease, pathological staging of radically 
removed prostate to assist the identification of capsule or seminal vesicle invasion, or positive 
surgical margin. 
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The TNM staging system proposed by the American Joint Committee on Cancer (AJCC) is 
the most frequently used clinical and pathologic staging system (Table 1) (18). Bone scan, 
computerized tomography (CT) or MRI is required to confirm potential metastasis of PCa 
tumors. 
 
Table 1. PCa staging. Leslie H. Sobin (Editor) MKGE, Christian Wittekind (Editor). 
International Union Against Cancer (UICC): TNM Classification of Malignant Tumours, 7th 
Edition. 7th Edition ed: Wiley-Blackwell; 2009 November. 
3 PROSTATE CANCER PROGNOSIS 
Since prostate cancer is a heterogeneous disease with different outcomes, an accurate 
prediction of prognosis is critically important prior to making a treatment decision. Currently, 
such a prognosis is based on PSA value, GS, clinical stage, age and comorbidity status. Based 
on the clinical diagnosis workflow (NCCN 2014 updated version, Figure 5) (19), we find that 
the current clinical guidelines for PCa management are mainly based on the estimation of life 
expectancy (LE) and classification by tumor risk factors. 
3.1 TUMOR RISK FACTORS 
The first and still most widely used tumor risk classification system is the D’Amico 
classification system, which stratifies patients with different risks of biochemical recurrence 
after prostatectomy or external radiation therapy (20-22). The D’ Amico risk system stratifies 
non-metastatic PCa patients into low-risk, intermediate-risk and high-risk subgroups based on 
initial PSA value, biopsy GS and clinical stage (22). The European Association of Urology 
(EAU) almost directly uses this system in the PCa management guidelines (Table 1) (19, 23). 
  7 
For staging, PCa can be classified as localized (T1-2N0M0), locally advanced (T3-T4N0M0) 
and metastatic (anyTN1anyM or AnyTanyNM1).
  
Table 1. The EAU guidelines for tumor risks definition, 2014 updated version. N. Mottet 
(Chair) JB, E. Briers (Patient Representative),, R.C.N. van den Bergh (Guidelines Associate) 
MB, N.J. van Casteren (Guidelines Associate) PC, S. Culine,, S. Joniau TL, M.D. Mason, V. 
Matveev, H. van der Poel,, T.H. van der Kwast OR, T. Wiegel. EAU Guidelines on Prostate 
Cancer-updated March 2015. 2015. English. 
The National Comprehensive Cancer Network (NCCN) guidelines classify tumors into very 
low, low, intermediate and high risk as clinically localized PCa, very high risk as locally 
advanced PCa, and metastatic PCa (Figure 5). The risk classification is based on the tumor 
risk factors as PSA value and density, GS, clinical stage, number of positive biopsies, 
cancerous area of core biopsies. 
 
Figure 5. Clinical diagnosis flowchart for prostate cancer. (NCCN clinical practice 
guidelines for prostate cancer, updated 2014). Mohler JL, Kantoff PW, Armstrong AJ, 
Bahnson RR, Cohen M, D'Amico AV, et al. Prostate cancer, version 2.2014. Journal of the 
National Comprehensive Cancer Network : JNCCN. 2014 May;12(5):686-718. PubMed 
PMID: 24812137. 
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3.2 PATIENT RISK FACTORS 
Besides the tumor risk factors, patient’s risk factors also contribute to the mortality of PCa. 
Age of patient at diagnosis is one of the most predominant risk factors for PCa mortality (24). 
Additionally, patient’s comorbidities and physical performance at diagnosis contribute to the 
non-prostate cancer-specific mortality (25, 26).  
3.3 LIFE EXPECTANCY ESTIMATION 
An estimation of life expectancy (LE) of newly diagnosed PCa patient determines the choice 
of primary treatment. In other words, LE estimation is crucial to determine whether the 
patient would benefit from active surveillance (AS) program, curative treatments such as 
prostatectomy and curative radiation therapy, or observation until symptoms for palliative 
treatments.  
Due to the slow progression of most PCa, several studies suggest a cutoff of 10-year LE to 
distinguish between aggressive and non-aggressive tumors. The 10-year LE rule is still the 
golden threshold for clinicians to select the treatment for PCa patients. On the other hand, it is 
difficult to estimate LE with satisfactory accuracy for treatment decision. There are other 
factors beyond tumor risk factors that cause the complexity of LE estimation, among which 
patient risk factors such as “biological age” and health status. Alternative LE estimation 
models based on the age and comorbidity have been reported with improved prediction 
accuracy of overall survival, particularly for non-cancer-specific survival (27). 
NCCN guidelines recommend the use of a nation-wide life-table analysis, such as the US 
Social Security Administration (SSA) life tables, when estimating LE (Figure 5 and 6).  SSA 
life tables are defined according to national social security data representing a population-
based general life expectancy. The estimation is fairly accurate (AUC=0.68 for 66 years old 
men), and independent of clinician’s expertise or experience (28). Comparatively, some LE 
prediction statistic models adjusted by comorbidities were reported to have more personalized 
survival estimation (29, 30). However, there is not sufficient evidence that these models 
would be more accurate than the SSA life tables (31). As pointed out previously, most of 
these studies mainly focus on the cancer-specific mortality or the effects contributed by 
cancer. There are only a limited number of studies investigating effects or parameters 
contributing to the non-cancer-specific mortality despite the observation that there are large 
numbers of PCa patients died of other diseases or diseases related to treatments. Investigating 
the specific causes of death (COD) causing non-cancer mortality is important to identify 
potential human risk factors, which is however very difficult to quantify. Therefore, design a 
biomarker research that could possibly establish a simple method to improve the accuracy of 
individualized LE estimation based on common tumor and patient risk factors and molecular 
biomarkers.  
4 PROSTATE CANCER TREATMENTS, CLINICAL 
OUTCOMES AND ENDPOINTS  
  9 
The selection of different treatment modalities is based on a balanced consideration of tumor 
risk factors, patient risk factors and LE estimation. Based on the most updated evidence and 
in line with the NCCN guidelines, Figure 6 presents different treatment options in relation to 
LE and different risk groups (32, 33). In NCCN guidelines (Figure 6), LE is considered as the 
conditional factor prior to choosing treatment due to the fact that elder patients with more 
comorbidities often benefit much less from any further active treatments. Instead, observation 
until obvious symptoms for palliative treatment is recommended for patients with short LE.  
4.1 ADT 
As mentioned earlier, clinically advanced very high risk PCa and metastatic PCa often 
undergo palliative hormone treatments or androgen deprivation therapy (ADT). ADT could 
be accomplished by surgical castration or by pharmaceutical agents such as anti-androgens, 
LH-analogs or antagonists (chemical castration). Because the growth and proliferation of 
prostate cancer cells requires the androgens, such as testosterone, ADT can lead to growth 
arrest and apoptosis of PCa cells, and even stromal fibrosis of PCa tissues (34). Despite a 
rapid response at the beginning, most cases will eventually progress and become metastatic 
CRPC (mCRPC) with median time to castration resistance of about 18 months (35). For 
mCRPC patients, many palliative treatments show modestly prolonged survival such as next 
generation of hormone therapy, chemotherapy including Docetaxel and Cabazitaxel, 
radiopharmaceutical therapy (Radium 223), and cancer immunotherapy. It is noteworthy that 
recent studies reported that chemohormonal therapy (ADT + chemotherapy) as the first line 
treatment for high risk PCa as well as metastatic hormone sensitive PCa could significantly 
prolong survival time (from 44.0 to 57.6 months) (32, 33, 36, 37).  
4.2 CURATIVE TREATMENT 
Curative RP (including laparoscopic or robotic-assisted prostatectomy) is the dominant 
treatment offered for patients with clinically localized cancer of low and intermediate risk, 
despite its modest clinical survival benefit (38). Curative RT is an effective treatment when 
combined with neo-adjuvant and adjuvant ADT for patients with high risk and locally 
advanced cancer (39-43). It is even recommended as a treatment option for patients with 
localized cancer of low to intermediate risk. For these patients, RT may have the same 
curative effect but different profile of complications and side effects as compared with RP. A 
recent study reported that even elder PCa patients could benefit more from curative RP or RT 
(44). For curative treatment, being cured is the most favorable clinical outcome that can be 
defined as after a sufficient long time of follow-up e.g. 10 years, there is no sign of 
recurrence. 
4.3 AS 
The AS program is preferably recommended for very low risk and low risk PCa patients, and 
is an effective way of compensating the disadvantage of early detection of PCa resulting in 
overtreatment currently. 
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Figure  6. PCa management and clinical outcomes. RT: Radiation therapy, RP: Radical 
prostatectomy, AS: Active surveillance, ADT: Androgen deprivation therapy, PLND: Pelvic 
lymph node dissection, BCR: Biochemical recurrence, CRPC: Castration resistant prostate 
cancer, mCRPC: metastatic CRPC. Risk groups are adopted from the NCCN clinical practice 
guidelines for prostate cancer, updated 2014 (http://www.nccn.org/) 
4.4 CLINICAL OUTCOMES AND ENDPOINTS 
Figure 6 also presents different progression steps and outcomes of PCa after the diagnosis. 
No matter which treatment, death would be the final outcome caused either by PCa disease or 
by other diseases or events. For AS, the most desirable outcome is the absence of 
progression, and thus no need for any further intervention. After radical treatment, some 
patients can suffer from recurrence by initially presenting an increase of PSA only, which is 
defined as the biochemical recurrence (BCR) or PSA relapse. Using BCR event as the 
endpoint of follow-up in clinical studies, the survival analysis can be defined as BCR free 
survival analyses. After BCR, a proportion of patients (with range of approx.15%-50% varied 
in different cohorts) can still be cured by salvage RT (45). Uncured patients will receive ADT 
treatment; however, despite a rapid response at the beginning, most cases will eventually 
progress and become metastatic CRPC and mCRPC is the major cause of cancer death for 
PCa patients. This means that overall mortality or survival is the utmost clinical outcome 
endpoint for PCa clinical studies. Time from diagnosis to death (overall survival time) is the 
most important variable to measure the treatment effect.  
Currently most PCa clinical studies, particularly those aiming at the identification of 
prognostic biomarkers, use surrogate endpoints such as adverse pathology, BCR or disease 
progression. These endpoints are clinically relevant but not like the utmost real clinical 
outcome endpoint: mortality with COD annotated and overall survival time. Thus biomarkers 
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identified based on surrogate endpoints would predict less relevant clinical outcomes instead 
of mortality with different CODs. The quality of life is gaining more attention than ever 
before since the radical treatments have become predominant in the past decades, and their 
severe side effects are dramatically affecting men’s normal life for the rest of their lives 
postoperatively. 
5 INACCURATE PROGNOSIS PREDICTION  
Obviously, a significant proportion of patients with low risk and perhaps even intermediate 
risk cancer have been treated by radical treatments unnecessarily (46). As stated above, the 
majority of indolent PCa patients are affected radical overtreatment according to the Prostate 
Cancer Intervention Versus Observation Trial (PIVOT), a randomized clinical trail. The 
study points, out that patients underwent RP do not benefit significantly from their treatment 
compared to the watchful waiting group during a12-year follow-up period (38). Another large 
randomized clinical trail, the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-
4), indicates however, that death numbers are less in the RP group (200/347) compared to 
watchful waiting group (247/348) after 23 years of follow-up (47). Nevertheless, clearly the 
majority of PCa patients appear over-treated (200/247=80.9% of RP treated PCa patients 
would not benefit more from their treatment than watchful waiting). 
These clinical challenges are fundamentally caused by inaccurate survival prediction at time 
of diagnosis, however the current clinical parameters just simply can not do more to get better 
prognosis prediction. A good cancer biomarker would offer a potential to further improve the 
current situation. The major reason of inaccurate prediction is that only using PSA, DRE and 
prostate biopsy, some actually high-risk cancers at early stage are mis-classified as low or 
intermediate-risk cancer, undergo AS program and thereby miss the best time window to be 
cured (48). It is not seldom that preoperative low GS and localized cancer becomes up-graded 
or up-staged postoperatively. Secondly, elder patients with high-risk cancer may be 
undertreated due to an inaccurate LE estimation (44). Furthermore, high-risk and locally 
advanced cancer needs extensive treatment more than just radical prostatectomy or local 
radiation (36). An improved prognosis prediction by integrating molecular biomarkers 
together with current common clinical parameters may lead to an optimized and 
individualized treatment selection, perhaps even for selection of suitable adjuvant hormone or 
chemotherapy in the near future. 
6 SWEDISH PATIENT COHORTS 
Sweden is a small country with a population of 9.5 million, the majority of them are 
Caucasian with a highly homogeneous ethnical background. Each person that is registered a 
resident in Sweden is assigned a unique personal number. By using this number, the clinical 
record of cancer patients is registered to one of the numerous nationwide cancer registries. 
These Regional Cancer Centers (RCC) are responsible for semiannual, regional registration 
and follow-up of clinical data of cancer patients. Each patient’s clinical record can be 
accessed by each individual clinical unit (local clinics, big hospitals, other clinical related 
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organization, etc.) by using the patient’s personal number. Thereby, the RCC has registered 
and automatically followed the clinical records for each cancer patient in this country for 
more than half a century. Moreover, there is a bio-bank law in Sweden that manages the 
patient samples. Assuming that patients have signed permits allowing the use of their material 
for current or future research, these samples could potentially contribute to many clinical 
studies. Every specimen shall be stored and kept in a proper way according to the bio-bank 
law.  
The complete registry data from RCC enables many translational researches to access one of 
the best clinically followed cohorts in the world, and more feasible accessed and well-
maintained human specimen bio-banks allow these studies could access to high-quality 
sample materials. Our studies, particularly the study in paper I, used fresh frozen fine needle 
aspiration (FNA) biopsy samples with up to 18 years clinically follow-up and nearly 90% of 
patients had been deceased until the endpoint. Consequently, these well documented and 
long-term followed clinical patient data allowed our study to access the ultimate clinical 
outcome: mortality with COD.  
7 CANCER BIOMARKERS 
The understanding of cancer at the molecular level has been deepened since the past decades, 
in particular due to the introduction of DNA, RNA and protein analyses in genome scale. It is 
generally accepted that cancer is a phenotype of genetic/genomic changes/mutations in the 
cells chromosomes (49). From phenotypic associations, molecular changes detected by whole 
genome analyses can be classified as: random mutations/changes, causative mutations, 
driving mutations/changes and disease associated mutations/changes. Except random 
mutations/changes, all other types have the potential to be further characterized as different 
types of biomarkers. Causative and driving mutations or changes can be further characterized 
as molecular targets for developing new effective treatments. 
A cancer biomarker is defined as a substance detected from tissue, blood, or other body 
fluids, which might indicate a sign of cancer, a degree of tumor aggressiveness, or the effect 
of drug pharmacodynamics (49). Cancer biomarkers help to distinguish different tumor 
subtypes of different aggressiveness or treatment sensitivities, and are therefore called 
predictive and prognostic biomarkers. The identification and application of prognostic 
biomarkers at the time of diagnosis would guide and improve treatment decision making for 
cancer management.  
7.1 PSA 
The prostate specific antigen (PSA) was identified as the first diagnostic biomarker for PCa 
in the early 1990s, and is one of the prognostic biomarkers used for risk classification in 
current clinical guidelines. As a classical blood diagnostic marker, a serum total PSA value of 
4.0ng/ml is the cutoff for PCa diagnosis (50). However PSA is prostate specific but not 
cancer specific, which leads to its limited specificity for diagnosing prostate carcinoma due to 
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hardly distinguishing from the PSA increase caused by benign prostatic hyperplasia (BPH), 
infection or chronic inflammation. The two major clinical trails reported recently that the 
potential of PSA screening for decreasing PCa mortality is becoming more controversial (4, 
5).  
As mentioned above, an increase of PSA value is one of mainstreamed biochemical 
recurrence biomarkers as the end-point of follow-up. It is a very convenient and practical 
biomarker for measuring the health status of the prostate gland since it can be assessed by a 
simple blood test. However there are some demerits to use an increase of PSA levels as the 
end-point for clinical studies in terms of LE estimation. Firstly PSA is only prostate-specific 
but not cancer-specific, which means the increase of PSA value does not necessarily related 
to a cancer event. Because its abnormal increased value in serum could possibly be caused by 
benign prostatic hyperplasia (BPH), infection or chronic inflammation. It is also known that 
poorly or non-differentiated prostate cancer doesn’t produce much PSA. Furthermore, the 
specificity of the PSA test itself is limited. Its value is also easily affected by prostate volume, 
age of patient and the dedifferentiation degree of the cancer cells. Several optimized PSA 
tests such as the prostate health index (PHI) test measuring three forms of PSA: total PSA, 
free PSA and p2PSA, would be a promising solution to provide more specific results (51). 
However, PSA recurrence (BCR) as an endpoint surrogate for real survival is unreliable. As 
described in the part of outcome and endpoints, treatments and outcomes after BCR can vary 
dramatically in different patients, some patients with BCR after surgery can even be cured by 
salvage RT. Using final end-point of follow-up such as ‘death of patient’ to generate overall 
survival rates for investigating LE prediction is more clinically reliable since it is also 
considering mortality due to other diseases or treatment related effects.  
7.2 GENOMIC BIOMARKERS 
Also in the 1990s, PCA3 was identified and is considered as the most PCa specific 
biomarker. It is a segment of non-coding RNA transcribed by chromosome 9q21-22 and can 
distinguish benign conditions from prostatic carcinoma with > 90% accuracy. PCA3 can be 
easily measured in urine samples. Unlike PSA, PCA3 measurement is not affected by 
prostate volume, patient’s age or any other prostatic disease such as prostatitis (52, 53). In 
2012, a commercial PCA3 urine test was approved by the US Food Drugs Administration 
(FDA); currently the test is recommended in European PCa management guidelines for 
guiding re-biopsy after the initial negative biopsy (23, 54). Its prognostic value in monitoring 
tumor progression status for those patients undergoing active surveillance (AS) program is 
still requiring more evidence to be confirmed (55). The use of PCA3 in combination with 
other biomarkers might improve its prognostic significance.  
A fusion protein consisting of transmembrane protease serine 2 (TMPRSS2) fused with the v-
ets erythroblastosis virus E26 homolog (avian) (ERG) gene (TMPRSS2-ERG) can be 
detected in approximately 40-80% of PCa urine samples (56). Using TMPRSS2-ERG to aid 
PCa diagnose have been investigated intensively recently, but its prognostic value in 
distinguishing aggressive from non-aggressive PCa remains to be established. Interestingly in 
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a prospective study, in combination with the urine biomarker PCA3, TMPRSS2-ERG 
appears to have increased prediction accuracy to distinguish tumors with higher GS>7 or 
clinically more significant tumors according to the Epstein criteria (57). The Epstein criteria 
identify insignificant or more significant tumors based on PSA density, Gleason score, 
number of positive cores and percentage of cancer area in each positive core (58).  
Deletion of a tumor suppressor gene, the phosphatase and tensin homolog on chromosome 10 
(PTEN), is widely associated with poorly differentiated prostate tumors. Loss of PTEN is 
associated with higher Gleason grade, risk of tumor progression and recurrence after 
treatment (59).  Deleted PTEN status is further associated with higher metastatic rates and 
cancer-specific mortality, particularly in combination with ERG/ETV1 rearrangement status 
(60). 
7.3 PROGNOSTIC BIOMARKERS  
A PCa predictive biomarker could guide and assist clinicians in the treatment decision-
making. This has been obtaining more attention over the years due to increased numbers of 
early detected and clinically insignificant prostate tumors, resulting in a large number of over-
treated patients. Moreover, due to the often uncertainty of choice making about preferable 
treatment for these early detected indolent PCa patients, better prognostic biomarkers 
providing a more accurate prediction as an improved supplement for current clinical 
standards are needed. Personalized genetic information extracted by biomarkers would aid 
clinicians to make treatment options with better survival prediction accuracy. Such 
biomarkers should be identified from studies with more relevant clinical end point and with 
longer period of follow-up, externally be validated and easily measured. There are a number 
of commercially available genetic prognostic tests that have been developed to guide 
treatment decision making for clinicians.  
Oncotype DX is a gene signature expression test based on a panel of 17 genes. The test 
measures mRNA expression levels of this gene panel using FFPE prostate core needle biopsy 
samples. The test has developed a new score called ‘Genomic Prostatic Score (GPS)‘, which 
stratifies indolent prostate cancer into very low-, low-, low-intermediate risks of subgroups 
with improved accuracy compared to the Cancer of the Prostate Risk Assessment (CAPRA) 
scores or the NCCN risks (61, 62). Both CAPRA and NCCN are scoring systems based on 
clinical parameters such as GS, pre-treatment PSA, clinical stage, proportion (%) of positive 
cores, and patient age at diagnosis (63). Thereby, the GPS provides genetic information in 
addition to conventional clinical parameters. A second study verified the prognostic value of 
the 17-gene signature in 402 patients including approximately 20% African American men. 
The test uses RT-qPCR, a standardized, precise and easily performed method to measure 
gene expression signatures. However the cohorts defined in both studies use BCR, i.e., 
increasing PSA levels after prostatectomy, as the follow-up endpoint, which is less clinically 
reliable in terms of overall or cancer-specific mortality.  
  15 
The Prolaris gene test is a gene signature expression test measuring the mRNA levels of 31 
cell cycle genes, also called the cell cycle progression (CCP) signature. Measuring the 
expression levels of CCP generates a CCP score to predict tumor progression status in terms 
of BCR occurrence following prostatectomy. The test has also been used to predict the 
mortality rate in a cohort of patients diagnosed by transurethral resection of the prostate 
(TURP) (64). A recent core needle biopsy cohort study with 558 patients shows that the CCP 
score is a strong predictor for PCa-specific 10-year mortality (65). In this study, the CCP 
score provides an independent additional prognostic value compared to other clinical scores 
such as CAPRA scores.  
It is a promising genomic biomarker test to predict 10 years PCa-specific mortality rate due to 
its clinical relevant follow-up endpoint of cohort and external clinical studies validated. The 
test could provide better guidance for clinician if more validation studies confirm its 
prognostic value in the future. However the test system is rather complicated as it is based on 
a panel of 31 genes requiring more advanced statistical data analyses compared to CAPRA 
scores. Although the CCP score showed comparable results compared to CAPRA score, and 
using the CCP score in combination with the CAPRA score can help to generate further 
improved prediction accuracy instead of using any of alone. Additionally, the test can only be 
performed in certified laboratories owned by the provider. Consequently, pathologists would 
be required to deliver the patient samples to a limited number of the provider certified 
laboratories from worldwide. Thereby, the cost of performing this test per patient poses a 
significant economic burden.  
As mentioned above the clinical endpoint is the most important aspect to evaluate the clinical 
relevance of prognostic biomarkers. Different endpoints could be used for different clinical 
indications such as adverse pathology, BCR after radical treatment, metastatic progression 
and death with specified COD (overall survival, cancer-specific or non-cancer specific 
survival time). Oncotype DX is based on results from clinical studies mainly using BCR or 
adverse pathology as the final endpoints, and Prolaris uses death with specified COD as 
endpoint (overall and cancer-specific mortalities) but not for non-cancer-specific mortality, 
which comprises the majority of deaths (Figure 6). PCa heterogeneity and more studies with 
clinically relevant outcome endpoints allow for the identification of better cancer biomarkers 
to improve overall survival estimation. 
8 EMBRYONIC STEM (ES) CELLS  
As introduced in an earlier section, genetic or genomic heterogeneity of PCa is the key 
feature to potentially identify more fundamental cancer biomarkers reflecting PCa tumor 
heterogeneity with different aggressiveness that consequentially determine different clinical 
outcomes. 
Embryonic stem (ES) cells are a type of undifferentiated cells capable of self-renewal and 
differentiating pluripotent. ES cells can be isolated from blastocysts, which are clusters of 50-
150 cells that develop 4-5 days post fertilization, at the so-called blastocyst stage (66). The 
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pluripotency of ES cells allows them to differentiate into any type of organ cells. During the 
organ forming stage, ES cells normally differentiate into tissue stem cells or tissue 
progenitors, eventually differentiated into terminal tissue cells.  
ES cell differentiation is a process of temporary loss of self-renewal and pluripotency, 
nowadays the induced pluripotent stem (iPS) cells technology has demonstrated that 
terminally differentiated cells can re-gain ‘stemness’ ability by artificially introducing a set of 
key iPS cell genes (67). Thereby the cell’s ‘stemness’, characterized by pluripotency and self-
renewal, indicates a potential plasticity. Previous studies reported that the gene expression 
patterns of ES cells could stratify tumor subtypes with different aggressiveness in terms of 
clinical outcome and therapy efficacy (68). Identification and isolation of a very small 
proportion of prostate cancer stem cells (CSCs) in order to identify the gene expression 
signature reflecting the ‘stemness’ is experimentally challenging. Instead, we aimed at 
finding the origin of ‘stemness’ from ES cells in our study I.  
Therefore we hypothesized that: 1) Genes that are important in maintaining ESC status and 
regulating cell differentiation are also important in abnormal differentiation 
(dedifferentiation). 2) Genes that show consistently high or consistently low expression levels 
across various ES cell lines are equally important in maintaining ESC status. Different 
expression patterns of these genes determine the development of different normal or cancer 
tissues. These genes are here named as ESCGPs (embryonic stem cell gene predictors). 3) 
These ESCGPs may be expressed in cancer cells and their expression levels can be measured 
by RT-PCR. 4) Different expression patterns of these ESCGPs measured in the cancer tissues 
can reflect cancer’s biological aggressiveness, and predict the efficacy of treatment and 
patient survival. 
9 SAMPLE TYPE 
Biomarkers can be measured in several types of samples, including blood, urine and tissue. 
Currently the most accessible sample types are blood and urine samples, such as PCA3 
measured in urine, PSA measured in blood. These types of samples are easy to collect and 
can be measured freshly no matter which type of molecules (i.e. nucleic acids or proteins). 
The disadvantage of these types of samples lies in the fact that they cannot be easily stored 
for longer period of time in contrast to FFPE samples. The FFPE method has been used for 
over a century to store tissue samples. Formalin fixation and paraffin embedding maintain 
tissue structure over decades, however the genetic materials (RNA and DNA) within FFPE 
tissue are dramatically damaged right after the fixation process. Although there are large 
amounts of FFPE tissue materials with good clinical follow-up data accessible for researchers 
compared other freshly frozen blood or tissue samples, FFPE tissue samples have not been 
utilized for molecular testing until recently. In recent times, updated technologies have been 
introduced such as Taqman® probe based RT-qPCR technology, specially optimized 
DNA/RNA sequencing technologies for FFPE tissue, and customized RNA/DNA extraction 
kits for FFPE tissue. 
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In a straightforward approach, molecular genomic tests using prostate FFPE tissue samples 
can extract genomic information directly from the prostate gland. As earlier mentioned, the 
Oncotype Dx and the Prolaris gene expression tests exploit prostate cancer tissue material 
from prostate FFPE core needle biopsy samples. For prostate needle biopsy samples, there is 
a practical issue that usually needs to be addressed. Needle biopsy samples often contain two 
types of Gleason patterns, e.g. Gleason grad 3 or 4. For experimental staff, it would be 
advantageous to know which histopathological type of cancer tissue should be taken counting 
into one sample measurement for single patient. Knowing that patients with different GSs 
show different survival rates, it would be practically relevant to evaluate whether gene 
signature expression levels are affected by different Gleason or other pathological patterns of 
cancer cells from the same patient.  
10 SAMPLE COLLECTION 
Prostate FFPE core needle biopsy samples often contain one or multiple prostate tissue cores 
taken by18-gauge needles, which is a very limited amount of tissue. Routinely paraffin 
blocker shall be prepared into 1-10µm thick of FFPE sections, which are then stained with 
hematoxylin and eosin stain (H&E) or by immunohischemical methods for cancer diagnosis.  
Apart from these sections that are used for diagnosis, the amount of remaining tissue that can 
be used for molecular genomic testing often is limited. Consequently genomic tests using 
prostate core needle biopsy tissue samples shall not require large amounts of tissue input. 
Prostatic cancerous cells easily grow in a cluster-like pattern presented in core needle biopsy 
samples, which allows manual isolation of cancer cells from FFPE sections become feasible. 
However even a single core biopsy also could contain multi-focal cancer cells, with relatively 
massive cells gathering together within each focus. In this case, neither manual scraping of 
cancer cells method nor laser micro-dissection method would make sample collection easier 
and efficient. The manual method is less precise while the micro-dissection method is time 
consuming for this mini-scale of tissue collection. A more precise, faster and cheaper method 
of sample collecting method would be favorable to do mini-scale of FFPE tissue collection.  
10.1 DIGITAL SCANNING 
The digital scanning technology can scan the H&E stained FFPE slides to obtain digital 
images containing a large range of magnifications from 1 up to 40 times. The quality of these 
digitally scanned, high-resolution images is favorable compared to traditional microscopy and 
meets the requirements for pathological diagnosis. The images can be uploaded and stored in 
a cloud-based server in an encrypted manner, which allows pathologists all over the world to 
practice their jobs only by logging in to this server, independent of their geographical location 
assuming that they have access to the internet. Digital images do not require large spatial 
volumes to store these archive stained slides. These advantages could dramatically decrease 
the cost of transporting histochemically stained slides, and allow pathologists across large 
distances in order obtain confirmed diagnosis. Furthermore, and the cost of storing archived 
slides can be greatly reduced. Moreover the digitalized imaging method would allow for a 
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more precise quantification of the cancer area compared to the traditional calculation method 
using length of cancer area in core needle biopsies. In our studies II and III, samples were 
taking manually guided by digitally scanned images. 
10.2 AUTOMATED SAMPLE COLLECTING SYSTEM 
After investigation in our studies, we are trying to introduce a digital image-guided and 
automated sample collecting system to collect the cancer area from prostate core needle 
biopsy FFPE sections (Figure 7). From each FFPE block, one H&E stained slide is prepared 
and serving as a ‘map’, and sequential FFPE sections are used for RNA extraction. The H&E 
stained slide can be scanned to generate digital images, which can be uploaded to an internet 
server in an encrypted manner, allowing pathologists to perform cancer cell marking and 
annotation with precise area calculations independent of their geographical location. An 
automated mini-dissection system, developed by an external provider, can use the digitally 
scanned image serving as a ‘digital map’ to guide its instrument to efficiently match and 
dissect the sequential FFPE sections with high precision and speed. This method allows 
sample taking of cancer cells from FFPE tissue sections with well-controlled precision, 
efficiency and automaticity. 
 
Figure 7. A digital image-guided and automated sample-collecting system. 
11 PROSTATYPE TEST SYSTEM 
There is need for a better prognostic biomarker indicating the utmost relevant clinical 
outcomes, such as estimating overall survival, PCa-specific survival and non-PCa specific 
survival. We are also aware of the significant contributions in terms of survival prediction 
from currently used clinical parameters such as GS, clinical stage, age at diagnosis, and PSA 
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value. Thus we performed a biomarker identification study based on ES cell theory in our 
first study, as the result, a three-gene signature was found showing independent prognostic 
significance in estimating overall survival time. Study II and III also verified the improved 
survival estimation accuracy by complementing gene expressions with conventional clinical 
parameters together in prostate FFPE core needle biopsy sample materials. Based on this 
finding, we transferred this invention into an industrialized project to develop an in vitro 
diagnostic (IVD) kit according to industrial regulatory standards such as ISO13485:2003 
(69).  The regulatory rules require standardized and comprehensive risk analyses, verification 
and validation plans in order to develop robust and to receive mandatory conformity marking 
approval in European area (CE marking) for the IVD test (Figure 8). The test should be 
qualified in many aspects such as transport stability, in-use stability, interfering substances, 
robustness, testing analytical performance and precision, tissue input, and reproducibility on 
three individual test sites (Figure 8). 
 
Figure 8. ISO13485:2003 regulatory procedures standardize the development of a 
industrial medical device product. Standardization of ISO13485:2003, Medical devices-
Quality management systems-Requirements for regulatory purposes 2003. Available from: 
http://www.iso.org/iso/home/store/catalogue_tc/catalogue_detail.htm?csnumber=36786. 
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11.1 PROSTATYPE RT-QPCR KIT 
The Prostatype Test System is composed of two parts. The first part is the Prostatype RT-
qPCR kit, a four multiplex one-step RT-qPCR kit, which can simultaneously measure 
expression levels of three-gene signatures and one housekeeping gene in one reaction well. 
Purified total RNA from tissue samples containing a minimum of 2/3 of cancer cells is the 
input material for this kit.  Within 1.5 hours, the expression levels of four genes can be 
measured.  
11.2 CPMA 
The second part of the Prostatype Test System is the Classification of Prostatic Malignancy 
Algorithm (CPMA), which is a software containing a large database. Based on the multiplex 
RT-qPCR reactions, the measured Ct values can be typed into the CPMA software together 
with four typical clinical parameters - age at diagnosis, pretreated PSA value, clinical stage 
and Gleason score - in order to generate the prognostic statement. The CPMA software 
contains a database that includes a large number of authentic, historical PCa patients’ clinical 
outcomes such as gene signature data, data regarding the four classic clinical parameters, and 
information on the treatment and overall survival time. In contrast to randomized selection, 
those authentic historical PCa patients included in the CPMA were selected aiming at the 
largest possible variety of clinical characteristics including death, COD, survival time, 
treatment, age, GS, clinical stage, and PSA value. The patients mainly originate from 
Scandinavian and Swiss populations with at least 7-11 years of follow-up.  The CPMA is 
being extended continuously and will be updated in specific time intervals. 
CPMA uses a K-nearest neighbor (kNN) algorithm to calculate the similarity distance of a 
newly diagnosed patient compared to any of neighbors in its reference database. The kNN is 
a non-parametric statistical model used for classification or regression (70). As a result, the 
CPMA, which uses the measured gene data in combination with the clinical data of a newly 
diagnosed PCa patient, could find the most similar three authentic historical PCa patients in 
the database. These three patients are presented together with information regarding their 
treatments and overall survival time. Instead of inventing a totally new scoring system which 
would require intensive correlation studies to current risk scores such as the NCCN risk 
score, the CPMA utilizes its large database to directly present the clinical records of the most 
relevant historical patients (living or deceased) in terms of treatment options and survival 
time. Additionally the information is supplemented with weighted gene signature data 
resulting in improved overall survival estimation accuracy.  Over time, the CPMA database 
would be expanded and thereby provide even better accuracy and precision by including 
patients from more various ethnicities, different PCa subtypes from different geographical 
regions. In a near future, a comprehensive CPMA database with big-data scale of genomic 
data and clinical outcome data would be a promising prognostic tool providing urologists, 
pathologists and oncologists an informative guidance to improve cancer management for PCa 
patients (Figure 9). 
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Compared to the two another prognostic biomarker tests, the Prostatype Test System is 
developed in a slightly less conventional manner (Table 3). Usually methods using FFPE 
cancer tissue to measure gene signature expression levels contain comprehensive steps in the 
test’s workflow. Conventionally these tests are developed as a laboratory-based service 
instead of a ready-to-use IVD test kit or system, which can be performed at any molecular 
laboratory equipped with a real time quantitative PCR machine.  This product type also 
dramatically decreases the additional transport costs of patient samples, and a digitalized 
CPMA software analysis method reduces time and manpower requirement. Thereby this test 
system has fundamental advantages for public health economy compared to the other two 
commercially available tests (Table 3).  
 In summary, the content of this thesis consists of (1) hypothesis-driven searching and 
identification of novel genomic biomarkers, (2) optimization of sample collection, (3) 
validation and verification of clinical indication of novel biomarkers, and potential integration 
of the industrially developed application into clinical situations.  
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    Oncotype ProstateDX® Prolaris® Prostatype® 
Developer   Genomic Health Inc Myriad Inc Chundsell Medicals AB 
Country   USA USA Sweden 
Signature Genes 12 genes from 4 pathways 31 cell cycle genes 3 embryonic stem cell gene predictors 
  Housekeeping genes 5 15 1 
  Total genes 17 46 4 
  Measuring method Two steps RT-qPCR Two steps RT-qPCR arrays One-step 4-plex RT-qPCR 
  Results calculating method 
Manually statistical 
calculation 
Manually statistical 
calculation CPMA database software 
  
Results GPS score  (Ref to NCCN risk scores) 
CCP score  
(Ref to CAPRA risk scores) 
3 closest authentic cases  
(Treatment/Overall survival 
time)   
Sample Type FFPE core needle biopsy FFPE core needle biopsy FFPE core needle biopsy 
  
Minimum input (n x 
thickness x length x 
width) 
6 x 5µm x 1.0 mm x 0.75mm 5 x 5µm x 2.0 mm x 0.75mm 6 x 10µm x 1.0 mm x 0.75mm 
  Minimum input (mm3) 0.0225 0.0375 0.05 
  Gleason pattern of cancer cells Not mentioned Not mentioned 
Any type of prostatic cancer 
cells 
  Cancer cells percentage  Not mentioned approx.>95% Not mentioned approx.>95% Verified >67% 
  Sample drop-out rate 7% 15% 17% 
 Test turnaround time Approx. 2-4 working days Approx. 2-4 working days 8 hours 
Clinical 
study Study patients number 382 585 241 + 420 + n 
  
Studies Endpoint Biochemical recurrence  PCa-specific death  Overall death, PCa/Non-PCa specific death   
Clinical 
application 
  
  
  
Prediction  BCR free survival  PCa-specific surivival  Overall survival, PCa/non-PCa specific survival 
Treatment indication Ref to NCCN Ref to CAPRA Historical treatments of 3 authentic cases 
Risk factors Tumor risk factors Tumor risk factors Tumor risk factors &  Patient risk factors 
Suitable patients Low risk PCa Any PCa Any PCa 
Product Business model  Lab based service Lab based service  CE marked Kit and CPMA software 
  Patent status US pending US pending Sweden approved, PCT phase 
  Laboratory requirement  Genomic Health's Labs Myriad's Labs Any pathology Labs 
  Price/Patient Approx. 4000 USD Approx. 3000 USD Approx. 10 000 SEK 
Table 3. Comparison of three prostate cancer biomarker tests. 
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Figure 9. Potential clinical application of the Prostatype Test System in the future. OS: 
overall survival, CS: cancer-specific survival, NCS: non-cancer-specific survival.  
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AIM OF THE THESIS 
Specific aims 
In this thesis work, we aimed at identifying genetic biomarker bases on the gene expression 
signature of ES cells, in order to stratify prostate tumor subtypes with different 
aggressiveness in terms of relevant clinical outcomes at time of PCa diagnosis. We further 
pursued validation of the prognostic value of the identified biomarkers in an external cohort 
with relevant clinical end-points and long-term follow-up. Moreover our goal is to implement 
the verified biomarkers into a clinical application, which could provide guidance for 
clinicians in the development of improved and personalized treatment decision for PCa 
patients. 
Paper I 
To identify genetic biomarker candidates from the ES cells based on their gene expression 
signature, the embryonic stem cell gene predictors (ESCGPs), to verify the certain key 
ESCGPs can classify tumor subtypes with overall survival differences in a long-term follow-
up Swedish fine needle aspiration biopsy cohort.  
Paper II 
To evaluate the identified gene signature (paper I) expression differences effect derived from 
the operator dependent choice of prostate cancer biopsy in FFPE core needle biopsy tissue 
material. 
Paper III 
To validate the prognostic value of the identified gene signature from paper I in an external 
population-based Swedish cohort with prostate FFPE core needle biopsy material, and to 
discuss the most optimal manner for implementing the newly identified biomarkers into 
clinical application.
  25 
RESULTS AND DISCUSSION 
Paper I 
An Expression Signature at Diagnosis to Estimate Prostate Cancer 
Patients Overall Survival 
We hypothesized that the gene expression signature of ES cells could determine the tumor 
subtypes with different levels of aggressiveness. To test this hypothesis, we developed and 
identified the embryonic stem cell gene predictors (ESCGPs) concept. The ESCGPs concept 
is based on the following assumptions: 1) Embryonic stem cells are the origin of tissue 
differentiated cells and tissue stem cells. 2) Genes that are important in maintaining ES cell 
status and regulating differentiation are also important in abnormal differentiation 
(dedifferentiation). 3) Genes with significant expression variations among different ES cell 
lines are not relevant in this respect. 4) Genes that show consistently high or consistently low 
expression levels across various ES cell lines are equally important in maintaining ES cell 
status. Different expression patterns of these genes determine the development of different 
normal or cancer tissue. These genes are here refereed to as ESCGPs. 5) These ESCGPs may 
be expressed not only in CSCs but also in cancer cells and their expressions can be measured 
by microarray, RT-PCR or qPCR. 6) Different expression patterns of these ESCGPs 
measured in the tumor tissues can reflect the cancer’s biological aggressiveness, and predict 
the efficacy of treatment as well as patient survival. 
The study results are presented as the following steps: 
Step 1: Identification of candidate ESCGPs  
From the Stanford Microarray Database (SMD), we retrieved previously published datasets 
of whole-genome cDNA microarrays of five human ES cell lines (71). These were 
normalized using the datasets of 115 human normal tissues including various organs (72).  A 
data subset with the whole-genome expression profile of 24361 genes in the ES cell lines was 
isolated. A single-class SAM (Significance Analysis of Microarrays) (73) was performed, 
whereby all genes were ranked according to the consistency (without significant variations) 
of their expression levels across the ES cell lines. As a result, SAM analysis of this data 
identified 328 genes with consistently high levels of expression and 313 genes with 
consistently low levels of expression in ES cells i.e. 641 ESCGPs in total. 
Step 2: Selection of candidate ESCGPs in prostate cancer 
An independent dataset (7) with 112 prostate tissue samples was used to verify the ESCGP 
findings and to select ESCGPs associated with PCa. The list of genes in the published dataset 
was matched to the list of the candidate ESCGPs identified in Step 1. The ability of the 641 
genes to classify tumor subtype was verified on an independent dataset of 112 PCa samples. 
In this analysis, the clustering result was almost identical compared to the complete original 
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data set of 5513 genes and the 258 PCa related ESCGPs isolated from the same original data 
set.  
Step 3: Refining ESCGPs selection using RT-PCR and multiplex qPCR analyses of three 
prostate cancer cell lines. 
A 4-plex qPCR method was optimized for the quantification of these genes by using RNAs 
from three prostate cancer cell lines (LNCaP, DU145, PC-3). Among the 258 verified 
prostate cancer ESCGPs, the 34 genes of highest-ranking order in the SAM analyses 
performed in step 2, were selected for follow-up analysis. In addition, 5 reported genes based 
on previously published studies were included in the same set. The 19 ESCGPs and 5 
reported genes were included in an optimization of the 4-plex qPCR using RNAs from 
prostate cancer cell lines, and ready to use for analysis of FNA samples taken from prostate 
cancer patients. 
Step 4: Establishing of the clinical relevance  
A Swedish cohort composed of 189 PCa patients diagnosed between 1986 and 2001 was 
studied to evaluate clinical relevance of the previous findings. Patient samples were collected 
by fine needle aspiration (FNA) cytology smear samples at the time of diagnosis, freshly 
frozen and stored until the time of analysis in 2008. The cohort was followed from diagnosis 
until December 31, 2008. At the end point of the study, 22 of the original 189 patients were 
still alive, 163 were deceased, and 4 could not be found in the registries. In a step-wise 
manner, the cohort’s gene profile was analyzed divided accordingly into three subsets of 
patients. 
Out of the 25 gene expression markers that were measured, 10 (F3, WNT5B, VGLL3, CTGF, 
IGFBP3, c-MAF-a, c-MAF-b, AMACR, MUC1 and EZH2) were significantly correlated 
with either overall or PCa-specific survival. Of more than 120 gene signature combinations 
derived from these 10 significant genes, a gene signature of three genes - IGFBP3, F3 and 
VGLL3 - showed the best stratification ability of tumor subtypes. For 87 patients, all clinical 
parameters were available and according to the expression of three-gene signature these 
patients could be categorized into three subtypes. The median overall survival time was 3.23 
years for patients with the high-risk subtype, 4.00 years for the intermediate-risk subtype and 
9.85 years for the low-risk subtype, and these values corresponded to hazard ratios of 5.86 
(95% CI 2.91-11.78, P<0.001) for the high-risk subtype and 3.45 (95% CI 1.79-6.66, 
P<0.001) for the intermediate-risk subtype compared to the low-risk subtype.  
The kNN classification algorithms were developed using the training set to estimate the 
overall survival (74). The performance of the kNN model using only clinical parameters was 
similar to the random model, whereas all kNN models including the selected ESCGP genes 
were significantly (P<0.04) better than the random model. Compared to the prediction model 
that used only the clinical parameters, when the combining three-gene signature and clinical 
parameters, the area under the curve (AUC) value was increased from 0.755 to 0.815 in 
  27 
overall survival prediction, from 0.726 to 0.793 in PCa-specific survival prediction, and from 
0.730 to 0.793 in Non-PCa specific survival prediction, respectively.  
In summary, the three-gene ESCGP signature is a promising biomarker combination suitable 
for estimating the survival of PCa patients. After validation in an independent cohort study, it 
would provide an important and orthogonal complement to the current clinical parameters 
that ate routinely used in the process of treatment decision for individual patients, in 
particular for patients diagnosed with early-stage PCa. 
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Paper II 
Operator dependent choice of prostate cancer biopsy has limited 
impact on a gene signature analysis for the highly expressed genes 
IGFBP3 and F3 in prostate cancer epithelial cells 
FFPE tissue material derived from either biopsy material or surgically removed tumors 
constitutes an appropriate and easily accessible sample. For PCa, FFPE core needle biopsies 
on which Gleason grading for diagnosis has been conducted, are readily available in the 
clinical routine pathology laboratories and suitable for such analyses. Typically, multiple 
biopsy samples were collected from each patient. Since Gleason grading is an operator 
dependent procedure known to be difficult, the impact of the operator’s choice of biopsy 
needs to be evaluated.   
Multiple biopsy samples from 43 patients were evaluated using the previously reported gene 
signature of IGFBP3, F3 and VGLL3 for their potential prognostic value in estimating overall 
survival at diagnosis of prostate cancer. A four multiplex one-step RT-qPCR test kit, 
designed and optimized for measuring this three-gene signature in FFPE core needle biopsy 
samples was used. Concordance of gene expression levels between primary and secondary 
Gleason tumor patterns, as well as benign tissue specimens was analyzed. 
We found gene expression levels of IGFBP3 and F3 in prostate cancer epithelial cell-
containing tissue representing the primary and secondary Gleason patterns were high and 
consistent. On the contrary, VGLL3 was expressed at markedly lower levels and showed a 
higher extent of variation in its expression levels. 
In summary the assessment of IGFBP3 and F3 gene expression levels in prostate cancer 
tissue is independent of Gleason patterns. Thereby, we can conclude that the impact of 
operator´s choice of biopsy is low. 
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Paper III 
Improving the prediction of prostate cancer overall survival by 
supplementing readily available clinical data with gene expression 
levels of IGFBP3 and F3 in formalin-fixed paraffin embedded core 
needle biopsy material. 
In a previous study performed by our laboratory, we showed that measurement of the 
expression levels of a three-gene signature (IGFBP3, F3 and VGLL3) in fresh frozen FNA 
cytology samples provides a reliable estimate of the overall survival time for PCa patients at 
diagnosis. The gene signature provided additional prediction power in terms of patients’ 
survival compared to the standard clinical parameters, such as age at diagnosis, cytology 
WHO grade, tumor stage and PSA value. Gleason score (GS) cannot be determined for FNA 
samples.  
In this work, we carried out a new cohort study with 241 prostate cancer patients diagnosed 
between 2004 and 2007 with a follow-up exceeding 6 years in order to verify the prognostic 
value of gene expression signature in FFPE prostate core needle biopsy tissue samples. The 
cohort consisted of four patients groups with different survival times and death causes. There 
were two groups of deceased cases, prostate cancer death within 5 years and death due to 
other diseases within 5 years. We used two control groups, one matched alive group where 
GS and age were matched to the deceased groups, and one randomly selected alive patient 
group. The main purpose of the study was to determine whether there are any differences in 
expression levels of IGFBP3 and F3 within these different patient groups with significantly 
different survival time. We also attempted to verify whether the gene signature combined 
together with current clinical parameters can provide higher prediction accuracy in terms of 
patients’ survival time, compared to the prediction solely based on clinical parameters. 
Our study presented in the paper II found the effect that operator dependent choice of FFPE 
core needle biopsy based Gleason pattern of epithelial cancer cells as basis for measurement 
of expression levels of IGFBP3 and F3 had limited impact on the results, when using the 
Prostatype RT-qPCR kit. The effect on VGLL3 measurements could not be estimated in that 
study due to limited tissue input. We only analyzed the gene expression levels of IGFBP3 and 
F3, measured only on the primary Gleason pattern tissue samples.  
Survival time predictions only based on the current clinical parameters, such as age at 
diagnosis, Gleason score, PSA value and tumor stage, were compared to survival estimations 
considering a combination of clinical parameters and expression levels of IGFBP3 and F3. 
The results of k Nearest Neighbor (kNN) analysis, multiple linear regression analysis and 
nominal logistic regression modeling showed that when combined with currently used 
clinical parameters, the gene expression levels of IGFBP3 and F3 could improve the 
prediction accuracy of survival time compared to using clinical parameters. 
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In summary, the assessment of IGFBP3 and F3 gene expression levels in FFPE prostate 
cancer tissue could provide an improved survival prediction for prostate cancer patients at the 
time of diagnosis. We provide evidence, that expression levels of IGFBP3 and F3 in 
combination with clinical parameters such as Gleason score most probably play an important 
role in the stratification of newly diagnosed prostate cancer patients. The results reported in 
this study warrants initiation of further investigations to evaluate the use of gene expression 
as a complement to clinical parameters to improve prediction accuracy of PCa prognosis. 
Studies with lager cohorts and survival follow-up exceeding 10 years would be required to 
further improve survival prediction and treatment choice. This could be particularly relevant 
for patients who could be safely assigned to active surveillance.
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FUTURE STUDIES AND PERSPECTIVE 
As an industrial sponsored PhD student associated both with an academic research institute 
(Karolinska Institutet) and a company (Chundsell Medicals AB), my research has always 
been performed with considerations of two perspectives: scientific and industrial. Industrial 
medical research is more focused on how to transfer and integrate scientific findings into 
routine clinical settings using applicable methodologies. Therefore my future research will 
continue to work on these projects that have both scientific and industrial aspects. 
Part I. Expanding the reference database of CPMA 
In paper III, we validated the prognostic value of two of three genes that were identified from 
in the cohort in paper I, even though it was challenging since the quality of the sample 
material was considerably much lower. More cohorts of clinical studies are needed to further 
validate the prognostic value of these two genes in a much larger number of patients, and 
patients from different countries should be included. At the same time, CPMA uses the kNN 
model to calculate the similarity of each parameter of each patient, in which the modeling has 
higher noise bias comparing to the conventional survival analyses. This means more patients 
filled in the reference database, more accurate kNN modeling prediction with lower noise 
bias.  
To expand the CPMA reference database, approximately 420 additional Swedish patients, 
diagnosed from 2004 to 2008, were selected and their samples are currently being tested. 
Some archive samples collected from patients are on the way to be filled in the CPMA 
reference database in the near future: about 200 from Sweden, 200 from Switzerland, and 
more than 200 from Germany. 
Part II. Developing the second version of the CPMA 
In paper II and III, VGLL3 has been excluded for further analyses and discussion, mainly due 
to the fact that average expression levels of this gene were relatively low in prostatic 
cancerous epithelial cells compared to IGFBP3 and F3. This causes higher noise of Ct values 
resulting in less reliable data, and further contributing to increased difficulty and complexity 
of analysis. However, interestingly, our unpublished data indicates that VGLL3 expression 
levels in prostatic benign cells were associated with survival time, which we did not publish 
in the previous studies. If this finding can be validated, the process of sample collection could 
be dramatically improved rendering the test system user-friendlier. Currently the test system 
requires that a minimum of 67.7% of cancer cells used for RNA isolation. If VGLL3 
expression in benign prostatic cells can be used to estimate survival time, this restriction 
might not be required anymore.  In that way, samples containing cancer cells and benign cells 
at any ratio or even benign cells alone could be utilized to generate relevant results.  
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Part III. Prospective clinical validation of the Prostatype Test 
System 
Ultimately, prospective clinical studies will be initiated once the Prostatype Test System is 
CE-marked according to regulatory rules in order to clinically validate the prediction 
accuracy when using the Prostatype test system in a prospective manner. After at least 5 years 
of follow-up, we could evaluate whether the initial survival prediction by the test system is 
accurate as compared with the real survival outcomes. With prospective clinical studies 
further validating the improvement of the Prostatype Test System, a shifting in clinical PCa 
management diagrams would be possible. It can be speculated that the proportion of patients 
who are recommended for an active surveillance (AS) program is going to increase (Figure 
10).   
  
Figure 10. Shifting of PCa treatments in the future.   
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